Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is gearing up to present two research and development showcase webinars for its two lead drug discoveries - PXS-5505, which targets several cancers, and PXS-6302, which targets the inhibition of scar tissue, especially trauma and burn scars.
The presentations will be hosted by globally renowned clinicians and scientists involved in the company’s clinical programs, then followed by a Q&A session spearheaded by a selection of biotech analysts and fund managers.
Pharmaxis’ cancer-targeting drug PXS-5505
Date and time: March 29, 2022 at 11.00am (AEDT)
Speakers:
- Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
- Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
- Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research
You can register for the event here.
Pharmaxis’ LOX and scarring inhibitor drug PXS-6302
Date and time: March 31, 2022 at 11.00am (AEDT)
Speakers:
- The science of scarring and potential for LOX inhibition - Dr Mark Fear, Senior Research Fellow University of Western Australia
- Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia
You can register for the event here.
Both webinars are free to attend and a recording of the event will be available on the Pharmaxis website.
About Pharmaxis
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis.
The company has a highly productive drug discovery engine, drug candidates in clinical trials and two respiratory products approved in global markets generating ongoing revenue.
Pharmaxis’ lead drug candidate (PXS-5505) is targeted for the treatment of the bone marrow cancer myelofibrosis, which affects 1 in 500,000 people.
Another Pharmaxis drug discovery, PXS-6302 has entered a world-first clinical trial aiming to stop scars that are formed after surgery or trauma, particularly following burn injuries.
Pharmaxis has also developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, and Aridol® for the assessment of asthma.
Both products are approved in major markets worldwide and sold through a network of commercial partners.